BD wins CE Mark for its Revello vascular covered stent for iliac artery disease, expanding its peripheral vascular portfolio in the growing PAD treatment market.
BDX wins FDA 510(k) clearance for Surgiphor 1000mL antimicrobial irrigation system, expanding its surgical irrigation portfolio with a powered lavage option.
Becton, Dickinson and Company (BDX) Q1 2026 Earnings Call Transcript
BDX posts an earnings beat with revenue growth and expanding margins in first-quarter fiscal 2026 quarter, though adjusted profit declined year over year.
Becton Dickinson (BDX) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.82 per share. This compares to earnings of $3.43 per share a year ago.
Get a deeper insight into the potential performance of Becton Dickinson (BDX) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
BDX completes a pilot with Envetec showing polystyrene Petri dishes can be safely recycled into new medical-grade feedstock.
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD launches BD Research Cloud 7.0 with AI-powered Horizon Panel Maker, boosting automation, data intelligence and productivity in flow cytometry.
Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Straumann Holding AG (SAUHY). But which of these two stocks offers value investors a better bang for their buck right now?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.